Nobuhiro Asai1,2, Wataru Ohashi3, Daisuke Sakanashi2, Hiroyuki Suematsu2, Hideo Kato2, Mao Hagihara2, Hiroki Watanabe1,2, Arufumi Shiota2, Yusuke Koizumi1,2, Yuka Yamagishi1,2, Hiroshige Mikamo4,5. 1. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, 480-1195 1-1 Yazakokarimata, Nagakute, Aichi, Japan. 2. Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute, Japan. 3. Division of Biostatistics, Clinical Research Center, Aichi Medical University Hospital, Nagakute, Japan. 4. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, 480-1195 1-1 Yazakokarimata, Nagakute, Aichi, Japan. mikamo@aichi-med-u.ac.jp. 5. Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute, Japan. mikamo@aichi-med-u.ac.jp.
Abstract
BACKGROUND: Candidemia has emerged as an important nosocomial infection, with a mortality rate of 30-50%. It is the fourth most common nosocomial bloodstream infection (BSI) in the United States and the seventh most common nosocomial BSI in Europe and Japan. The aim of this study was to assess the performance of the Sequential Organ Failure Assessment (SOFA) score for determining the severity and prognosis of candidemia. METHODS: We performed a retrospective study of patients admitted to hospital with candidemia between September 2014 and May 2018. The severity of candidemia was evaluated using the SOFA score and the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score. Patients' underlying diseases were assessed by the Charlson Comorbidity Index (CCI). RESULTS: Of 70 patients enrolled, 41 (59%) were males, and 29 (41%) were females. Their median age was 73 years (range: 36-93 years). The most common infection site was catheter-related bloodstream infection (n=36, 51%).The 30-day, and in-hospital mortality rates were 36 and 43%, respectively. Univariate analysis showed that SOFA score ≥5, APACHE II score ≥13, initial antifungal treatment with echinocandin, albumin < 2.3, C-reactive protein > 6, disturbance of consciousness, and CCI ≥3 were related with 30-day mortality. Of these 7, multivariate analysis showed that the combination of SOFA score ≥5 and CCI ≥3 was the best independent prognostic indicator for 30-day and in-hospital mortality. CONCLUSIONS: The combined SOFA score and CCI was a better predictor of the 30-day mortality and in-hospital mortality than the APACHE II score alone.
BACKGROUND:Candidemia has emerged as an important nosocomial infection, with a mortality rate of 30-50%. It is the fourth most common nosocomial bloodstream infection (BSI) in the United States and the seventh most common nosocomial BSI in Europe and Japan. The aim of this study was to assess the performance of the Sequential Organ Failure Assessment (SOFA) score for determining the severity and prognosis of candidemia. METHODS: We performed a retrospective study of patients admitted to hospital with candidemia between September 2014 and May 2018. The severity of candidemia was evaluated using the SOFA score and the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score. Patients' underlying diseases were assessed by the Charlson Comorbidity Index (CCI). RESULTS: Of 70 patients enrolled, 41 (59%) were males, and 29 (41%) were females. Their median age was 73 years (range: 36-93 years). The most common infection site was catheter-related bloodstream infection (n=36, 51%).The 30-day, and in-hospital mortality rates were 36 and 43%, respectively. Univariate analysis showed that SOFA score ≥5, APACHE II score ≥13, initial antifungal treatment with echinocandin, albumin < 2.3, C-reactive protein > 6, disturbance of consciousness, and CCI ≥3 were related with 30-day mortality. Of these 7, multivariate analysis showed that the combination of SOFA score ≥5 and CCI ≥3 was the best independent prognostic indicator for 30-day and in-hospital mortality. CONCLUSIONS: The combined SOFA score and CCI was a better predictor of the 30-day mortality and in-hospital mortality than the APACHE II score alone.
Authors: Otavio T Ranzani; Elena Prina; Rosario Menéndez; Adrian Ceccato; Catia Cilloniz; Raul Méndez; Albert Gabarrus; Enric Barbeta; Gianluigi Li Bassi; Miquel Ferrer; Antoni Torres Journal: Am J Respir Crit Care Med Date: 2017-11-15 Impact factor: 21.405
Authors: Luis Ostrosky-Zeichner; Bart Jan Kullberg; Eric J Bow; Susan Hadley; Cristóbal León; Marcio Nucci; Thomas F Patterson; John R Perfect Journal: Med Mycol Date: 2010-09-06 Impact factor: 4.076
Authors: Eamon P Raith; Andrew A Udy; Michael Bailey; Steven McGloughlin; Christopher MacIsaac; Rinaldo Bellomo; David V Pilcher Journal: JAMA Date: 2017-01-17 Impact factor: 56.272
Authors: David L Horn; Dionissios Neofytos; Elias J Anaissie; Jay A Fishman; William J Steinbach; Ali J Olyaei; Kieren A Marr; Michael A Pfaller; Chi-Hsing Chang; Karen M Webster Journal: Clin Infect Dis Date: 2009-06-15 Impact factor: 9.079
Authors: Gregory A Eschenauer; Peggy L Carver; Shu-Wen Lin; Kenneth P Klinker; Yee-Chun Chen; Brian A Potoski; Ryan K Shields; Cornelius J Clancy; Minh-Hong Nguyen; Simon W Lam Journal: J Antimicrob Chemother Date: 2012-12-04 Impact factor: 5.790